Insmed reported $361.29M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Cytokinetics USD 178.28M 21.06M Jun/2025
DBV Technologies USD 41.11M 13.74M Jun/2025
Dynavax Technologies USD 81.01M 10.78M Jun/2025
Gilead Sciences USD 4.35B 80M Jun/2025
Insmed USD 361.29M 20.33M Jun/2025
Novartis USD 9.37B 782M Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Sarepta Therapeutics USD 495.51M 549.73M Jun/2025
Ultragenyx Pharmaceutical USD 274.38M 7.85M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025